Skip to main content
. Author manuscript; available in PMC: 2011 Jul 1.
Published in final edited form as: Leuk Res. 2009 Dec 4;34(7):877–882. doi: 10.1016/j.leukres.2009.11.007

Table 2.

Response Following FLAM Induction Therapy

CR NR NE

All Patients (n=45) 30 (67%) 11 (24%) 4 (9%)
Response by Age
    ≤ 50 (n=5) 3 (60%) 0 (0%) 2 (40%)
    51–59 (n=16) 14 (88%) 1 (6%) 1 (6%)
    ≥ 60 (n=24) 13 (54%) 10 (42%) 1 (4%)
Response by Poor Risk Biologic Features
  Etiology
    MDS/AML (n=23) 15 (65%) 7 (30%) 1 (4%)
    MPD/AML (n=5) 2 (40%) 3 (60%) 0 (0%)
    T-AML (n=9) 8 (89%) 0 (0%) 1 (11%)
  Genetics
    Adverse Cyto (n=24) 16 (67%) 7 (30%) 1 (3%)
    FLT-3 (n=9) 8 (89%) 0 (0%) 1 (11%)
  Proliferation
    Blasts ≥ 20,000/mm3 (n=15) 9 (60%) 5 (33%) 1 (7%)
    Pretreatment HU (n=6) 3 (50%) 2 (33%) 1 (17%)